Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05434156
PHASE1/PHASE2

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

Sponsor: Eleusis Therapeutics

View on ClinicalTrials.gov

Summary

A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).

Official title: A Phase I, Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous Doses of ELE-101 in Healthy Adult Participants (Part 1) and Part 2, Open-Label Study to Evaluate a Range of Pharmacodynamic Effects of a Single Intravenous Dose of ELE-101 in Patients With Major Depressive Disorder.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

84

Start Date

2022-10-27

Completion Date

2026-03

Last Updated

2025-02-19

Healthy Volunteers

Yes

Interventions

DRUG

ELE-101

ELE-101 solution for intravenous infusion

DRUG

ELE-101 Placebo

ELE-101 placebo matching solution for intravenous infusion

Locations (2)

MAC Clinical Research

Liverpool, United Kingdom

MAC Clinical Research

Manchester, United Kingdom